# Complement-mediated anti-pneumococcal functions of C-reactive protein

> **NIH NIH R01** · EAST TENNESSEE STATE UNIVERSITY · 2021 · $370,000

## Abstract

Project Summary / Abstract
C-reactive protein (CRP) was discovered in the blood obtained from patients infected with Streptococcus
pneumoniae and was found to be a component of innate immunity and inflammatory response. In murine
models of infection, human CRP is protective against lethal infection with S. pneumoniae. The mechanisms of
anti-pneumococcal action of CRP are not defined yet. Interestingly, CRP was protective only during the early
stages of infection, i.e., when CRP was injected into mice within 6 h of administering pneumococci. CRP was
not protective during the late stages of infection, i.e., CRP was not protective when injected into mice after 6 h
of administering pneumococci. In vitro, CRP binds to phosphocholine groups present in the cell wall C-
polysaccharide of pneumococci and subsequently activates the complement system. Accordingly, it is
hypothesized that CRP is protective because ligand-bound CRP activates the complement system on the
pneumococcal surface leading to the reduction of bacteremia. This hypothesis explains the protective effects of
CRP during the early stages of infection, but this does not explain why CRP loses its protective effect during
the late stages of infection. We hypothesize that CRP works through two mechanisms: one mechanism based
on the binding of CRP to phosphocholine and subsequent complement activation and one mechanism based
on the binding of CRP to complement inhibitor factor H. This hypothesis will be tested in the following three
specific aims. In aim 1, the hypothesis that “the activation of the complement system on the pneumococcal
surface, subsequent to the binding of CRP to pneumococci, participate in CRP-mediated protection” will be
tested. In aim 2, two hypotheses that “pneumococci recruit complement inhibitory protein factor H on their
surface and evade complement attack during late stage infection” and that “structurally altered CRP capable of
binding to factor H can protect mice against infection during the late stages also” will be tested. In aim 3, the
hypothesis that “the binding of CRP to phosphocholine groups is critical for complement activation and killing of
pneumococci” will be tested. These hypotheses will be tested by using mutants of CRP incapable of activating
murine complement, capable of binding to factor H, and incapable of binding to phosphocholine and by
employing both wild-type and CRP knockout mice. Successful completion of this project will provide insight into
the mechanisms of anti-pneumococcal functions of CRP which may lead to the development of a CRP-based
strategy to treat late stage pneumococcal infection.

## Key facts

- **NIH application ID:** 10098301
- **Project number:** 5R01AI151561-02
- **Recipient organization:** EAST TENNESSEE STATE UNIVERSITY
- **Principal Investigator:** ALOK AGRAWAL
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $370,000
- **Award type:** 5
- **Project period:** 2020-02-05 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10098301

## Citation

> US National Institutes of Health, RePORTER application 10098301, Complement-mediated anti-pneumococcal functions of C-reactive protein (5R01AI151561-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10098301. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*